Literature DB >> 17322577

The Pro12Ala polymorphism of the PPAR gamma 2 gene influences sex hormone-binding globulin level and its relationship to the development of the metabolic syndrome in young Finnish men.

Firoozeh Mousavinasab1, Tuula Tähtinen, Jari Jokelainen, Pentti Koskela, Mauno Vanhala, Jorma Oikarinen, Markku Laakso, Sirkka Keinänen-Kiukaanniemi.   

Abstract

Association of low sex hormone-binding globulin (SHBG) level with the risk of the metabolic syndrome (MetS) in men has previously been reported. A proline to alanine substitution in codon 12 of the peroxisome proliferator activated receptor gamma 2 (PPARgamma2) gene has been shown to be related to high insulin sensitivity. The relationship of SHBG levels with the Pro12Ala polymorphism of PPARgamma2 in men has not been previously studied. Therefore, we investigated the effect of the Pro12Ala polymorphism of PPARgamma2 on SHBG levels in 202 young Finnish men. The range of SHBG was from 3.30 to 73 nmol/L (geometric mean = 17.90; 95%CI = 16.62-19.25 nmol/L). Baseline SHBG levels tended to be lower in men who developed the MetS (n = 11) compared to men who did not develop the MetS (n = 169) (22.85 vs 17.26 nmol/L) on a high-caloric diet during their 6 mo military service. SHBG levels tended to be higher among the subjects with the Ala12Ala genotype compared to subjects with the Pro12Pro or Pro12Ala genotypes of the PPARgamma gene (27.7 vs 21.7 and 22.7 nmol/L). Among the carriers of the Pro12Pro genotype, those who developed the MetS (n = 8) had significantly lower levels of SHBG compared to men who did not develop the MetS (n = 93) (13.23 vs 24.22 nmol/L, p = 0.027). Among the subjects who developed the MetS those with the Pro12Pro genotype (n = 3) had significantly lower levels of SHBG compared to subjects with X12Ala (n = 8) (13.23 vs 28 nmol/L, p = 0.025). We conclude that the 12Ala allele of PPARgamma2 may influence SHBG levels in young Finnish men.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17322577     DOI: 10.1385/ENDO:30:2:185

Source DB:  PubMed          Journal:  Endocrine        ISSN: 1355-008X            Impact factor:   3.633


  20 in total

1.  Metabolic and ovarian effects of rosiglitazone treatment for 12 weeks in insulin-resistant women with polycystic ovary syndrome.

Authors:  Nicholas A Cataldo; Fahim Abbasi; Tracey L McLaughlin; Marina Basina; Patricia Y Fechner; Linda C Giudice; Gerald M Reaven
Journal:  Hum Reprod       Date:  2005-09-09       Impact factor: 6.918

2.  Peroxisome proliferator-activated receptors and insulin secretion.

Authors:  Yasuo Terauchi; Takashi Kadowaki
Journal:  Endocrinology       Date:  2005-08       Impact factor: 4.736

3.  Testosterone selectively reduces the high molecular weight form of adiponectin by inhibiting its secretion from adipocytes.

Authors:  Allen D Seftel
Journal:  J Urol       Date:  2005-09       Impact factor: 7.450

4.  Effect of rosiglitazone on insulin resistance, C-reactive protein and endothelial function in non-obese young women with polycystic ovary syndrome.

Authors:  Ilhan Tarkun; Berrin Cetinarslan; Erdem Türemen; Tayfun Sahin; Zeynep Cantürk; Baki Komsuoglu
Journal:  Eur J Endocrinol       Date:  2005-07       Impact factor: 6.664

5.  Lack of increase of serum adiponectin concentrations with a moderate weight loss during six months on a high-caloric diet in military service among a young male Finnish population.

Authors:  Firoozeh Mousavinasab; Tuula Tähtinen; Jari Jokelainen; Pentti Koskela; Mauno Vanhala; Jorma Oikarinen; Sirkka Keinänen-Kiukaanniemi
Journal:  Endocrine       Date:  2005-02       Impact factor: 3.633

6.  Endogenous sex hormones and metabolic syndrome in aging men.

Authors:  Majon Muller; Diederick E Grobbee; Isolde den Tonkelaar; Steven W J Lamberts; Yvonne T van der Schouw
Journal:  J Clin Endocrinol Metab       Date:  2005-02-01       Impact factor: 5.958

7.  Effects of rosiglitazone in obese women with polycystic ovary syndrome and severe insulin resistance.

Authors:  Vicken Sepilian; Manubai Nagamani
Journal:  J Clin Endocrinol Metab       Date:  2004-10-13       Impact factor: 5.958

8.  Testosterone and sex hormone-binding globulin predict the metabolic syndrome and diabetes in middle-aged men.

Authors:  David E Laaksonen; Leo Niskanen; Kari Punnonen; Kristiina Nyyssönen; Tomi-Pekka Tuomainen; Veli-Pekka Valkonen; Riitta Salonen; Jukka T Salonen
Journal:  Diabetes Care       Date:  2004-05       Impact factor: 19.112

9.  A Pro12Ala substitution in PPARgamma2 associated with decreased receptor activity, lower body mass index and improved insulin sensitivity.

Authors:  S S Deeb; L Fajas; M Nemoto; J Pihlajamäki; L Mykkänen; J Kuusisto; M Laakso; W Fujimoto; J Auwerx
Journal:  Nat Genet       Date:  1998-11       Impact factor: 38.330

10.  Sex hormones, inflammation and the metabolic syndrome: a population-based study.

Authors:  David E Laaksonen; Leo Niskanen; Kari Punnonen; Kristiina Nyyssönen; Tomi-Pekka Tuomainen; Riitta Salonen; Rainer Rauramaa; Jukka T Salonen
Journal:  Eur J Endocrinol       Date:  2003-12       Impact factor: 6.664

View more
  7 in total

Review 1.  Management of obesity in the elderly: too much and too late?

Authors:  R L Kennedy; U Malabu; M Kazi; V Shahsidhar
Journal:  J Nutr Health Aging       Date:  2008-11       Impact factor: 4.075

Review 2.  Diverse roles for sex hormone-binding globulin in reproduction.

Authors:  Geoffrey L Hammond
Journal:  Biol Reprod       Date:  2011-05-25       Impact factor: 4.285

Review 3.  Genetics of metabolic syndrome.

Authors:  Tisha Joy; Piya Lahiry; Rebecca L Pollex; Robert A Hegele
Journal:  Curr Diab Rep       Date:  2008-04       Impact factor: 4.810

4.  Variants in the HMG-CoA reductase (HMGCR) gene influence component phenotypes in polycystic ovary syndrome.

Authors:  Ning Xu; Kent D Taylor; Ricardo Azziz; Mark O Goodarzi
Journal:  Fertil Steril       Date:  2009-03-26       Impact factor: 7.329

5.  Crosstalk between circulating peroxisome proliferator-activated receptor gamma, adipokines and metabolic syndrome in obese subjects.

Authors:  Khadijeh Mirzaei; Arash Hossein-Nezhad; Seyed Ali Keshavarz; Fariba Koohdani; Ali Akbar Saboor-Yaraghi; Saeed Hosseini; Mohammad Reza Eshraghian; Mahmoud Djalali
Journal:  Diabetol Metab Syndr       Date:  2013-12-12       Impact factor: 3.320

6.  Associations of Sex Steroids and Sex Hormone-Binding Globulin with Non-Alcoholic Fatty Liver Disease: A Population-Based Study and Meta-Analysis.

Authors:  Xiaofang Zhang; Yuchan Mou; Elif Aribas; Masoud Amiri; Jana Nano; Wichor M Bramer; Maryam Kavousi; Robert J de Knegt; Eralda Asllanaj; Mohsen Ghanbari
Journal:  Genes (Basel)       Date:  2022-05-27       Impact factor: 4.141

Review 7.  Plasma steroid-binding proteins: primary gatekeepers of steroid hormone action.

Authors:  Geoffrey L Hammond
Journal:  J Endocrinol       Date:  2016-04-25       Impact factor: 4.286

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.